- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 04.06. | JOYZYME GROUP (08622): SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO THE AGM CIRCULAR | - | HKEx | ||
| 29.05. | JOYZYME GROUP (08622): NOTICE OF ANNUAL GENERAL MEETING | - | HKEx | ||
| 29.05. | JOYZYME GROUP (08622): FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON FRIDAY, 26 JUNE 2026 AT 4:00 P.M. (OR AT ANY ADJOURNMENT THEREOF) | - | HKEx | ||
| JOYZYME GROUP Aktie jetzt für 0€ handeln | |||||
| 29.05. | JOYZYME GROUP (08622): (1) PROPOSED RE-ELECTION OF RETIRING DIRECTORS; (2) PROPOSED RE-APPOINTMENT OF AUDITOR; (3) PROPOSED GRANTING OF GENERAL MANDATES ... | - | HKEx | ||
| 28.05. | JOYZYME GROUP (08622): PROPOSED AMENDMENTS TO THE MEMORANDUM AND ARTICLES OF ASSOCIATION AND ADOPTION OF AMENDED AND RESTATED MEMORANDUM AND ARTICLES ... | 1 | HKEx | ||
| 27.04. | JOYZYME GROUP (08622): ANNUAL REPORT 2025 | - | HKEx | ||
| 30.03. | JOYZYME GROUP (08622): COMPANY INFORMATION SHEET | - | HKEx | ||
| 30.03. | JOYZYME GROUP (08622): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | - | HKEx | ||
| 30.03. | JOYZYME GROUP (08622): RESIGNATION OF NON-EXECUTIVE DIRECTOR | - | HKEx | ||
| 27.03. | JOYZYME GROUP (08622): ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2025 | 1 | HKEx | ||
| 17.03. | JOYZYME GROUP (08622): NOTIFICATION OF BOARD MEETING | - | HKEx | ||
| 09.02. | JOYZYME GROUP (08622): COMPANY INFORMATION SHEET | - | HKEx | ||
| 04.02. | HUAKANG BIOMED (08622): (1) CHANGE OF COMPANY NAME (2) CHANGE OF STOCK SHORT NAME (3) CHANGE OF COMPANY LOGO (4) CHANGE OF COMPANY WEBSITE | - | HKEx | ||
| 15.01. | HUAKANG BIOMED (08622): POLL RESULTS OF EXTRAORDINARY GENERAL MEETING HELD ON 15 JANUARY 2026 | - | HKEx |
14 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| IMMUNOME | 19,330 | 0,00 % | Immunome Inc. - 8-K, Current Report | ||
| VERA THERAPEUTICS | 38,200 | 0,00 % | Vera Therapeutics Announces Alignment with U.S. FDA on Earlier ORIGIN Phase 3 Analysis to Support Potential Full Approval for Atacicept in Adults with IgA Nephropathy | Prescription Drug User Fee Act (PDUFA) date of July 7, 2026 for Biologics License Application (BLA) for accelerated approval of atacicept in patients with IgA Nephropathy (IgAN)Revised ORIGIN 3 eGFR... ► Artikel lesen | |
| ADITXT | 0,042 | 0,00 % | Aditxt, Inc. - 8-K, Current Report | ||
| PRAXIS PRECISION MEDICINES | 305,35 | -0,01 % | Praxis Precision Medicines, Inc. - 8-K, Current Report | ||
| KYMERA THERAPEUTICS | 98,15 | -0,10 % | Kymera Therapeutics (KYMR) Soars 10.0%: Is Further Upside Left in the Stock? | ||
| DISC MEDICINE | 70,45 | 0,00 % | Disc Medicine Inc: Disc Medicine Provides Update from FDA Type A Meeting for Bitopertin in Erythropoietic Protoporphyria | Aligned with the FDA that the Phase 3 APOLLO study, if successful, can serve as the basis for CRL response and could potentially support a traditional approvalOn track for expected CRL response submission... ► Artikel lesen | |
| BOUNDLESS BIO | 2,610 | +0,38 % | Boundless Bio, Inc.: Boundless Bio and Serapha Bio Announce Merger Agreement and $230 Million Concurrent Private Placement | Combined company to operate as Serapha Bio and to advance Serapha's potential best-in-class in vivo base editing program for Alpha-1 Antitrypsin Deficiency Serapha's lead program SERP-01 targets the... ► Artikel lesen | |
| KAILERA THERAPEUTICS | 21,370 | 0,00 % | Kailera Therapeutics, Inc.: Kailera Reports First Quarter 2026 Financial Results and Provides Clinical Data Updates | Important progress across four clinical-stage programs demonstrating depth and breadth of obesity pipeline Initiated five late-stage global clinical trials in obesity, including the ribupatide injection... ► Artikel lesen | |
| ENLIVEN THERAPEUTICS | 48,590 | -0,02 % | Hedge Fund and Insider Trading News: John Paulson, Warren Buffett, Ray Dalio, Brevan Howard, Rokos Capital Management, Noble Corp PLC (NE), Enliven Therapeutics Inc (ELVN), and More | ||
| NURIX THERAPEUTICS | 18,860 | 0,00 % | Nurix, BioNxt Solutions, Zealand Pharma - Neue Therapien sorgen für Fantasie | Der Biotech-Sektor erlebt derzeit eine Phase enormer Dynamik. Besonders Therapien gegen Adipositas, Diabetes, Autoimmunerkrankungen und neurologische Leiden zählen zu den größten Wachstumsmärkten im... ► Artikel lesen | |
| KINIKSA PHARMACEUTICALS | 59,50 | +0,02 % | Kiniksa Pharmaceuticals Aktie markiert Rekordhoch bei 59,89 USD | ||
| TREVI THERAPEUTICS | 17,370 | -0,06 % | Trevi Therapeutics Aktie erreicht Rekordhoch von 16,13 USD | ||
| ERASCA | 15,070 | 0,00 % | Erasca, Inc.: Erasca Reports First Quarter 2026 Business Updates and Financial Results | Robust monotherapy efficacy and generally well-tolerated safety results observed during dose escalation for ERAS-0015 in both KRAS G12X NSCLC and PDAC reinforce best-in-class potential across RAS-targeted... ► Artikel lesen | |
| DYNE THERAPEUTICS | 20,240 | -0,10 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces Expanded Debt Facility of Up To $400 Million with Hercules Capital, Inc. | - Up to $125 million in additional borrowing capacity provides further strategic flexibility - - $50 million of additional capacity funded at amendment closing - WALTHAM, Mass., June 17, 2026 (GLOBE... ► Artikel lesen | |
| ARRIVENT BIOPHARMA | 33,740 | 0,00 % | ArriVent BioPharma, Inc. - 8-K, Current Report |
Das Unternehmen JOYZYME GROUP LTD kann der Branche Biotechnologie zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu JOYZYME GROUP LTD finden Sie auf Wallstreet Online.